openPR Logo
Press release

Rising Incidence of Cervical Cancer Worldwide Drives Cytology and HPV Testing Market

05-30-2017 03:48 PM CET | IT, New Media & Software

Press release from: TMR - Research Reports

Rising Incidence of Cervical Cancer Worldwide Drives Cytology

The competitive landscapes of the cytology testing market and the human papillomavirus (HPV) testing market are both oligopolistic in nature. Transparency Market Research has found that a handful of large companies have been enjoying dominance over the global scenario, thereby reducing the level of competition and making the entry of new players extremely difficult.

This 109 page report gives readers a comprehensive overview of the Cytology and HPV Testing Market. Browse through 16 data tables and 38 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/cytology-hpv-testing-market.html

Qiagen N.V., Hologic, Inc., and F.Hoffman-La Roche AG together enjoy a massive 86% of the HPV testing market. “Considering that the market shares of the first and second place companies catering to the demand for HPV testing are rather close, upcoming approvals for new screening tests are likely to have a significant impact on their position in the market,” the author of the study states. For instance, the 2014 approval of Roche’s cobas HPV test by the U.S. Food and Drug Administration (FDA) has resulted in the upsurge of the company’s market share from what it was a couple of years ago.

Similarly, Hologic and Becton Dickinson account for 89% of the cytology testing market. The only competition observed by TMR in this area of the market is currently in the segment of Pap tests in the U.S., which is a lucrative avenue for cytology testing. However, non-FDA approved tests also pose a threat to the present status of players.

“Companies in the overall cytology and HPV testing market have been relying on international expansions and collaborations to retain their dominance,” the analyst states. Direct engagement with diagnostic laboratories and contracting with governments for patient care programs are also a few key strategies adopted by the players.

Disparate Levels of Awareness among Patients Regarding Cytology and HPV Testing

The growing incidence of cervical cancer as well as HPV infections is the single most important factor driving the demand for cytology and HPV testing. The number of new cases of cervical cancer and the number of deaths resulting from this chronic condition have propelled patients to opt for early detection and diagnosis methods. The rise in awareness about the commercial availability of screening tests has driven the adoption of cytology testing. The high incidence rate of HPV infections and growing awareness regarding the threat that these infections pose to the immune system have fueled HPV testing and Pap smear screening.

However, TMR has observed that several emerging markets present a similar challenge. “The lack of access to better healthcare and infrastructure for women and the presence of outdated facilities in most developing countries restrict the large-scale adoption of cytology and HPV testing,” the analyst states.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving Cytology and HPV Testing Market by 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2216

Cytology and HPV Testing Services to Continue Leading Streak

The global market for cytology and HPV testing is projected to expand at a rapid pace over the coming years, with the value rising from US$7.9 bn in 2015 to US$10.5 bn by 2024. North America is the largest as well as the fastest expanding regional market in terms of revenue and this segment is poised to develop at a 3.3% CAGR during the forecast period to reach US$5.8 bn by 2024. While HPV testing services dominate the HPV testing market by revenue, assays kits are anticipated to register the highest CAGR of 10.1% from 2016 to 2024. On the other hand, the cytology testing market is led by cytology testing services and cytology testing assay kits are likely to expand at a 5.1% CAGR, the fastest among other sub-segments.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rising Incidence of Cervical Cancer Worldwide Drives Cytology and HPV Testing Market here

News-ID: 556658 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for HPV

Human Papillomavirus (HPV) Vaccines Market is Thriving Worldwide with Top Compan …
Los Angeles, United State, –The report titled Global Human Papillomavirus (HPV) Vaccines Market is one of the most comprehensive and important additions to QY Research’s archive of market research studies. It offers detailed research and analysis of key aspects of the global Human Papillomavirus (HPV) Vaccines market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete
HPV Vaccines Market 2020-2026 - COVID19 Impact On HPV Vaccines Industry | Top Ke …
HPV Vaccines Market Size, Share & Industry Analysis, By Type (Bivalent and Polyvalent), By Disease Indication (HPV Associated Cancer and Genital Warts), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others) and Geography Forecast, 2019-2026. Get Sample Copy Of Report To Know The Impact of Covid19 on this Industry: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/human-papillomavirus-hpv-vaccines-market-101962 Top Key Players: GSK, Merck. An Overview of the Impact of COVID-19 on HPV Vaccines Market: The emergence of COVID-19 has brought
HPV Testing & PAP Test Market by Test Type (HPV Testing, Follow-up HPV Testing, …
Global HPV Testing & PAP Test Market was valued at USD XX billion in the year 2017. Global HPV Testing & PAP Test market is further estimated to grow at a CAGR of XX % from 2018 to reach USD XX billion by the year 2023. Get Free Access to Sample Report @ https://genesismarketinsights.com/Sample_Request/GENRE385 In the Global HPV Testing & PAP Test Market, by region, North America holds the highest market share
Human Papillomavirus (HPV) Therapeutics Market to Reach US$2.34 bn by 2020, Driv …
Human papillomavirus (HPV) and cytomegalovirus (CMV) are viral pathogens affecting individuals of all ages. HPV causes serious sexually transmitted diseases (STDs), while CMV is an opportunistic pathogen affecting immunocompromised individuals such as HIV patients. The global market for HPV and CMV therapeutics is expected to experience a surge due to various macro and micro economic factors. Read the Comprehensive Overview of Human Papillomavirus (HPV) Therapeutics Market:
Cytology and HPV Testing Market: Disparate Levels of Awareness among Patients Re …
Over the years, the level of awareness among the global population regarding the various types of cancer has increased tremendously. The significance of early detection and diagnosis is not lost on them, resulting in the increased adoption of screening tests such as cytology and human papillomavirus (HPV) testing. The global market for cytology and HPV testing is presented with a host of sustained growth opportunities arising mainly from several emerging economies,
New Research: Global Human Papillomavirus (HPV) Market
MarketResearchReports.Biz presents this most up-to-date research on "Human Papillomavirus (HPV)- Epidemiology Forecast To 2023" Latest Report, Human Papillomavirus (HPV) - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Human Papillomavirus (HPV) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Human Papillomavirus (HPV) prevalent or incident cases segmented by age, sex and subpopulations. The